Table 4 Effectiveness (% (95% CI)) of full series of rotavirus vaccine* against rotavirus disease stratified by age, Bolivia
| Subgroups | Non-diarrhea controls† | Test negative controls‡ | |||
|---|---|---|---|---|---|
| Crude | Adjusted | Crude | Adjusted | ||
| Rotavirus hospital admission | |||||
| All ages | 80 (70 to 86) | 77 (65 to 84) | 70 (53 to 80) | 69 (54 to 79) | |
| Age 6-11 months | 79 (57 to 90) | 77 (51 to 89) | 65 (38 to 80) | 64 (34 to 80) | |
| Age ≥12 months | 78 (62 to 87) | 76 (59 to 86) | 76 (62 to 87) | 72 (52 to 86) | |
| Vesikari score ≥11 (severe diarrhea) | |||||
| All ages | 79 (68 to 85) | 76 (64 to 84) | 70 (56 to 79) | 69 (53 to 79) | |
| Age 6-11 months | 79 (58 to 89) | 78 55 to 91) | 66 (39 to 81) | 66 (34 to 82) | |
| Age ≥12 months | 78 (63 to 87) | 76 (59 to 86) | 77 (62 to 87) | 72 (51 to 86) | |
| G9P[8] hospital admission | |||||
| All ages | 86 (71 to 93) | 85 (69 to 93) | 80 (64 to 89) | 80 (60 to 90) | |
| Age 6-11 months | 89 (65 to 97) | 90 (65 to 97) | 81 (51 to 92) | 82 (59 to 92) | |
| Age ≥12 months | 83 (59 to 93) | 82 (47 to 94) | 78 (73 to 95) | 78 (46 to 91) | |
*Cases and controls were considered vaccinated with respective number of doses (one, two, or three) if most recent dose was administered ≥14 days before date of case’s hospital visit.
†Because non-diarrhea controls were matched on age and hospital, conditional logistic regression was used to compute odds ratio for vaccination versus no vaccination; crude vaccine effectiveness includes only vaccination in model; adjusted vaccine effectiveness for model with hospital admission includes sex, day care, and computer for 6-11 months and sex, number of children, and rooms for ≥12 months; model for Vesikari ≥11 includes sex, day care, and telephone for 6-11 months and sex and number of children and rooms for ≥12 months; model for Vesikari ≥15 includes none for 6-11 months and sex and number of rooms for ≥12 months.
‡Unconditional logistic regression was used to compute odds ratio for vaccination versus no vaccination among cases and test negative controls; crude vaccine effectiveness adjusts only for month/year of birth and hospital; adjusted vaccine effectiveness for model with hospital admission and Vesikari ≥11 includes month/year of birth, hospital, sex, and day care for 6-11 months and month/year of birth, hospital, and day care for ≥12 months; adjusted model for G9P[8] includes month/year of birth and hospital for 6-11 and ≥12 months.